Almirall, S.A.

Thank you very much Nadia. Good morning everyone.

Thank you for joining us for today's quarterly earnings update and review of Almirall's 2024 full year financial results. As always, we are sharing the slides we are using today in the Investors section of our website at almirall.com.

Please move to slide number two. Let me remind you that the information presented in this call contains forward-looking statements, which involve known and unknown risks, uncertainties and other factors that may cause actual results to materially differ from what we are sharing today.

Please move to slide number three. Presenting today we have Carlos Gallardo, Chairman and Chief Executive Officer; Mike McClellan, Chief Financial Officer; and Karl Ziegelbauer, Chief Scientific Officer.

Carlos will start with a strategic overview and mid-term guidance, the business highlights covering 2024 and will also give us an update specifically on our biologic portfolio as key growth drivers in our medical dermatology portfolio. Karl will provide you with an R&D status update highlighting the progress of our pipeline.

Mike will then talk you through the financials before Carlos close and we open up for your questions. Now I will hand over to Carlos Gallardo, our Chairman and CEO for an introduction.

Thank you very much Pablo and good morning to everyone in the call. So 10 years ago we took the strategic decision to focus exclusively on medical dermatology, as we anticipated a fast growing market, driven by the tremendous unmet need of patients suffering with skin conditions, but also because of the increased understanding of disease biology on a number of diseases.

Today, I'm happy to say that we call it right. Medical dermatology is already a 46 billion market worldwide and poised to grow 7.5% on a compounded annual growth rate.

In this context, we have executed very well on our strategy having been able to either source or to internally develop products in all these key categories. As a reminder, the growth of this market is being driven today, thanks to the biologics in psoriasis and in atopic dermatitis and that's where we have our key products, Ilumetri and Ebglyss.

But also let's not forget that we have other very exciting programs that are helping patients tremendously, such as Decoderm, Klisyri, Ciclopoli and more recently Jublia that will contribute to drive the growth of this company going forward. Since I became CEO two years ago, we saw this tremendous opportunity in this nice and growing market.

So we've been focusing on investing to make sure we could deliver on the biologics and we could position Ebglyss and Ilumetri as key first line products in moderate to severe patients. I'm happy to say that everything is working according to plan and we entering a new era of accelerated growth and margin expansion.

In addition to working in building the right capabilities to maximize the growth and the potential of these brands, we were also focusing, of course, in shaping the future, in getting ready to deliver the next wave of innovation in our labs in Sant Feliu, but also in sourcing externally the next wave of innovation to continue to grow the company in the years to come. A few weeks ago I was in San Francisco at the JP Morgan Healthcare Conference and we provided mid-term guidance for the first time that I'm happy to reiterate and confirm today.

We envisage double-digit sales compounding annual growth rate from now until the end of the decade and EBITDA to continue to expand up to around 25% by 2028 and this is while keeping our R&D investment rate at around 12%. Moving into the guidance, I'm delighted to say that we have surpassed our 2024 guidance and we have delivered double-digit net sales growth versus the high-single digit that we had anticipated 12 months ago and EBITDA as well, we anticipated a range of 175 million to 190 million and we have surpassed this range landing in 192.6 million.

Moving into this year and very aligned with the mid-term guidance that we signaled or we commented a number of weeks ago. Now we're going to be doing what we've been done 2024 that is executing well on the launches and executing well in the R&D front.

So we envisage to accelerate our net sales growth from 10% to 13% this year and EBITDA again aligned with the guidance, EBITDA margin expansion, we expect to land the EBITDA between 220 million and 240 million in 2025. Moving to the next slide, if we double click on 2024 and some highlights what has worked well, I would highlight that what has worked well is the execution.

The capability of our teams to execute consistently on our strategy ranging from pricing to market access, to marketing, to commercial, and every single department across the value chain has delivered flawlessly in 2024. I'm going to take this opportunity also, as I know that some of my colleagues are connected to the call to congratulate them, because the performance in 2024 has been fantastic and the beginning of 2025 seems to be very strong as well.

I'm not going to dwell on the finances as we have recommended on them, but in terms of the key growth drivers, great growth in the biologics continue to gain market share both in psoriasis and endotopic dermatitis, but also not forgetting our other growth drivers such as Klisyri and Wynzora that have performed extremely well. Moving to R&D pipeline, we have continued in 2024 to develop our pipeline and Karl will comment on the different specifics, but I would like to highlight the inclusion of two new assets in our clinical stage and the [Indiscernible] and the Anti-IL-21.

So, going back to the biologics, if we move forward to the next slide, please, we can see that combined we expect to reach more than 800 million and this guidance on peak sales was also updated during the JP Morgan conference. Again, this is a testimony of the markets that are growing very well, the classes where we have our assets are becoming the winning classes and also we continue and we envision to continue to gain market share in this market, thanks to the great execution of our teams, and the strong partnering that we have with dermatologists.

If we move into the psoriasis market in particular, what we can see here is how the psoriasis market has evolved in the past 10, 15 years. We have seen that has grown exponentially, thanks to the inclusion of new asset classes and new technologies.

And we could look at the market and think that this is already a mature market, but it's not the case because these 365,000 patients represent only around 20% of the number of eligible patients for this type of advanced treatments, advanced systemic treatments. So there's still tremendous opportunity for market expansion.

There's a tremendous opportunity to continue to help patients through partnering with dermatologists and this is our modus operandi, this is our strategy. Within this context and within this quickly expanding market, our product Ilumetri has continued to perform really well and has performed very well because, one, as I said before, we're in a nicely growing market.

Within this nicely growing market, our mechanism of action, the anti IL-23, has become in Europe, the winning class, the go to class for dermatologists to treat moderate to severe patients. And within this class, we are gaining market share.

And we're gaining market share because of the great profile, because of the great execution of our teams, because of our strong partner with dermatologists. And also I would like to remind you that last year we launched a 200 milligram presentation, which is providing additional flexibility to prescribers to achieve their treatment goals and in particular with these patients that are overweight or have a high burden of disease.

We don't think that these dynamics are going to change in the near future. We expect these dynamics to continue in 2025 and beyond.

Moving to the topic dermatitis and this slide showing a little bit the market and market evolution. We see atopic dermatitis market very similar to the psoriasis market but we are around 10 years where the psoriasis market was.

We see today that there are at least 2023, there were 81,000 or 82,000 patients treated that is less than 10% of the total number of eligible patients. So, tremendous growth and we see this market to continue to grow in the year to come.

And we look at 2031 estimates as that there will be 400,000 patients treated and we believe that this projection probably is a bit conservative. So again, we see tremendous opportunity in this market to continue to help patients, and this market will continue to expand until 2030 and beyond.

Within this favorable backdrop, we launched -- next slide, please, we launched in Germany in late 2023, so we had now a full year of commercialization of the product in Germany. And we are delighted to see how the product is performing in this key market.

We have achieved already the second largest dynamic new patient share in Germany. The feedback that we're getting from physicians is very good and we already have thousands of patients in therapy.

Also we have launched already in other countries, but remind you that this 33 million that we have achieved in 2024 are coming largely from Germany, because in the other countries that we launched in 2024, we are still in the market access stage. So we are getting the product in the formularies, we're getting the product in the different hospitals, and in some cases we have to go either region by region or hospital by hospital.

However, this effort is going to pay off this year in 2025. So you can expect this year 2025 to see a continued strong contribution from Germany, but already a sizable contribution from the other markets.

If we move to the next slide, this illustrates the launch sequence. As I said before, we launched in Germany in late 2023 and a number of additional countries in 2024.

And from these countries, these six countries, we should already start to see a strong contribution in 2025. In 2025 we have launched in a number of additional countries or we are planning to launch.

There will be up to 12 countries in 2025. I have to say that the execution in terms of pricing and market access is going everything either according to plan or sometimes surpassing expectations.

For example, in Spain we've been able to achieve reimbursement six months ahead of what typically takes and the same thing in some cases in other countries. Not only the price that we are achieving, but also sometimes in how quickly we're achieving these prices.

And I think that's a great testimony again of our ability to execute, but also what we're finding is that payers want these products and this is helping us a lot to accelerate our agenda in this front. So far things going very well, at least in 2024 with Ilumetri and Ebglyss and we anticipate this dynamic to continue 2025 and beyond.

Next, if we move to the next slide, I invite Karl to give us an update on the positive progress in R&D and our pipeline.

Yeah, thank you Carlos and like to welcome everybody. Thanks for joining our call today.

You can see on that slide the progress of our pipeline. As you may recall, in October last year we successfully completed the decentralized regulatory approval procedure for Efinaconazole in Europe.

The decentralized procedure completion is the final step before national marketing authorization can be granted by European countries. Work with the national regulatory authorities is now underway and marketing authorizations are expected during the first half of 2025.

Sarecycline's regulatory review in China is ongoing. You may know that timelines are more volatile for regulatory procedures in China and we now expect approval in the second half of 2025.

For Klisyri expansion to large field in Europe, we are currently running a clinical study aiming to launch in 2026. Together with our partners, we continue to work on expanding the labels for our key products Ilumetri and Ebglyss.

Our partner Sun Pharma is running two Phase III studies to assess the efficacy and safety of Tildrakizumab in patients suffering from psoriatic arthritis. First results are being expected in the second half of 2025.

To make Ebglyss available to all patients with moderate to severe atopic dermatitis Our partner Eli Lilly is running a Phase III study exploring the safety and efficacy of Lebrikizumab in patients 6 months to under 18 years. We have created an exciting pipeline of early clinical assets with novel mechanisms and best-in-class compounds addressing high medically skin diseases.

In the next 15 months we plan to initiate four proof-of-concept clinical studies across a spectrum of different skin diseases. Clinical supply manufacturing for our Anti-IL-21 monoclonal antibody is ongoing to prepare for phase 2.

IL-21 is a cytokine affecting both D and T cell biology and hypothesized to be involved in several immune mediated skin diseases. For our Anti-IL-1RAP monoclonal antibody we have completed Phase I single and multiple ascending doses in healthy volunteers.

Now pharmacokinetics and safety are being explored in patients. We plan to start a Phase II study later this year in Hidradenitis suppurativa high medicated indication.

For our IL-2 mutant fusion protein, Phase I single and multiple ascending doses are ongoing. This IL2 mutant fusion protein activates regulatory T cells with the potential to treat various autoimmune diseases.

ZKN-013 is an Oral Readthrough Inducer designed to overcome nonsense mutations that cause a premature stop codon. ZKN-013 has utility in several rare indications such as Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa and familial adenomatous polyposis.

Phase I is ongoing. In summary, we're making good progress with both our early and late stage pipeline.

Let's now move to Slide 20. In medical dermatology, there is still a high medical need and many patients suffering from diseases for which there is no adequate treatment.

With our comprehensive capability across the entire value chain from discovery to commercialization, we're ideally positioned to address this medical need and build an inventive discovery pipeline with significant potential. Our strategy is to combine internal discovery with in-licensing assets at various stages.

Our internal capabilities focus on disease understanding while working with specialized technology provider to select the best modality for a given target or therapeutic approach. We are working with mRNA, LNPs, small molecules, antibodies, bispecific and other modalities.

We have a bispecific monoclonal antibody for atopic dermatitis in preclinical development and multiple early discovery programs covering a broad range of skin diseases. Next slide please.

To maximize the value of Ebglyss, we are conducting together with our partner Eli Lilly a comprehensive clinical development program. Details on the different studies are available in the appendix.

In addition, we will complement our excellent clinical data package with real world evidence studies. One example is the so called ADTrust study.

ADTrust is a 1,200 patient pan-European prospective observational two year study that aims to explore the physical, psychological and social impact of atopic dermatitis on patients life aligned with our noble purpose. The objective is to assess disease symptoms, severity, control of skin manifestations, patients perception of their skin and personal well being, patient quality of life, treatment effectiveness, safety and satisfaction in patients with moderate to severe atopic dermatitis receiving leprecizumab over a period of 24 months in real world clinical practice settings.

The first patient was recruited into the study in January 2025 and we anticipate the study finishing in 2028. With that I will hand over to Mike for the financial review.

Thank you, Karl, for providing an insightful overview of the new Ebglyss studies and the developments in our pipeline. As Carlos mentioned earlier, we were able to slightly surpass our 2024 guidance for sales and EBITDA, reaching an inflection point for future growth.

We delivered a great performance for the full year of 2024 with a net sales increase of 10.2% driven primarily by strong growth in our European Dermatology portfolio which is a key pillar in our journey towards leadership in medical dermatology. We achieved a total EBITDA of 1.92.6 million in 2024, a growth of 10.6% versus 2023 largely driven by strong sales growth while still investing more in R&D and SG&A supporting our new launches.

Our gross margin was in line with guidance at 64.7% of sales, as we experienced some pressure from the increased telemetry royalties as we have hit higher sales levels. SG&A in 2024 was up 10% to $464.6 million primarily due to investments in the Ebglyss launch across Europe supporting the brand's growth trajectory in 2025 launch countries.

R&D investment was up 11.9% year-on-year representing 12.6% of net sales. This is aligned with our annual target and our pipeline strategy to fuel long-term innovation.

We ended 2024 with a net debt to EBITDA ratio of 0.2 times, which positions us well to take advantage of potential licensing or bolt on M&A opportunities. Let's move to the details of our sales breakdown on Slide 24.

The European dermatology business delivered a very robust performance with 22.5% year-on-year growth, which I'll cover in more details on the next slide. Our general medicine OTC business performance in Europe delivered a slight growth in 2024, aided by the growth in Ebastel and Almax, which offset further generic pressure for Efficib and Tesavel.

I'll share more details in the US on the next slide and the performance of the rest of the world general medicine business increased mainly due to strong results from Ebastel. Let's take a closer look at the dermatology business on the next slide.

Our European dermatology segment continues to excel, primarily driven by our biologics Ilumetri and Ebglyss. Other derm growth drivers such as Klisyri and Wynzora continue to expand in key European markets.

After just one year on the market, Ebglyss has achieved $33.2 million in sales, positioning it as one of our leading contributors. This result is in line with our expectations and continues to bolster our confidence in its robust growth trajectory.

Ilumetri delivered another strong year of growth, reaching more than 200 million and putting it on track for the new peak sales that Carlos mentioned of more than 300 million. The US business is stabilizing with Seysara sales growing double digit in 2024.

The positive impact of the recent large field launch in Klisyri in August is starting to take effect and the overall volume is growing since the launch. However, the US legacy business remains under pressure from ongoing generic pressure related to Cordran and Tazorac.

However, Axon [Phonetic] sales have increased here on. Rest of the world dermatology sales experienced a slight decline due to lower sales of Ciclopoli and less licensing income from non core products.

Let's now move on to the complete financial statements. As we've covered sales, let's review the rest of the P&L.

Gross margin for 2024 was 64.7%. We anticipate continued gross margin pressure in the coming years due to the sales mix and higher royalty tiers, primarily for Ilumetri as its sales increase.

Our R&D investments have risen to 12.6% in net sales, up from 2023 and we expect this level to remain in 2025 to support our innovation and pipeline strategy. SG&A investments have grown by 10% compared to 2023, mainly driven by the Ebglyss launches and pre-launch activities for the 2025 countries.

Financial expenses decreased, benefiting from higher interest income on short-term cash deposits. Keep in mind that our effective tax rate is influenced by the inability to offset US tax losses against our profitable European business.

We also had some minor impairments due to the US Legacy business, particularly Cordran and Tazorac. Please move to the next slide to take a look at the balance sheet.

The main highlight to call out on the balance sheet is the effect of the investments in intangible assets throughout the year. In the first half these include the $10 million upfront payment for the IL-21 asset from Novo Nordisk, a smaller upfront payment for the read through inducer from Eloxx Pharmaceuticals, and in the second half we have had minor investment to acquire the remaining Klisyri global rights.

We also have a 45 million Ilumetri sales milestone which will be paid in 2025. This is due to hitting higher levels of sales of the product.

We also have a minor sales milestone related to Wynzora as well as some capitalization of Ebglyss Phase IV studies. The total impact has been counterbalanced by depreciation for the year and a minor impairment of the US legacy assets I mentioned on the previous slide.

Please note that our net debt ratio remains favorable at 0.2 times despite significant cash outflows during the year, which we will review in more detail on the next slide. So let's now turn to the cash flow statement.

We generated an operating cash flow of $160.8 million in 2024, a significant improvement from 2023 due to flat working capital. Other adjustments mainly relate to net financial income including interest from short-term deposits.

Our investing activities saw notable cash outflow in 2024, primarily from 2023 milestones that were paid in early 2024. In January, we had a 45 million payment for Ebglyss first commercial sales in the EU and a 20 million milestone payment for Ilumetri sales.

We expect an additional 45 million Ilumetri sales milestone which was triggered in Q4 to be paid in the first half of 2025. The divestments refer to milestones in royalties collections from the AstraZeneca/Covis arrangement.

Overall, we generated a positive free cash flow, despite the heavy investments made in 2024. I will now give some more color on our 2025 guidance that was given by Carlos.

Getting into the details of the 2025 guidance, I'd like to outline that some guidance assumptions we are using for 2025, which include some pushes and pulls. We anticipate the increase in net sales mainly coming from continued growth of Ilumetri in Europe and the further uptake of Ebglyss including new launches in several countries.

We will as well have growth of Klisyri and Wynzora across Europe, while the rest of the portfolio will be relatively stable this year. We will continue to experience slight gross margin pressure giving increased royalty rates, particularly from Ilumetri.

R&D investment is expected to stay around the 12% of net sales level as we've seen in recent years. In 2025 and going forward we expect the net sales growth to accelerate faster than the SG&A growth rate.

SG&A growth will slow significantly in 2026 and beyond once the Ebglyss launches have been rolled out across Europe. Regarding the tax rate, it should land somewhere in the mid-40 range in 2025 before declining in 2026 and beyond into the mid-20s, as the US tax loss impact diminishes and the growth of biologics in Europe will allow us to utilize more of our R&D tax credits.

Finally, bear in mind that the guidance range does include the small out licensing that we announced in January. The full year effect will only be slightly more than 2024 as we've had small activities each year as part of our portfolio optimization strategy and out licensing of non-core product lines.

With this I will hand it back to Carlos for some closing remarks.

Thank you very much Karl and Mike for your updates. So to close, we have had significant market opportunity in front of us, nice market, growing market, a tremendous opportunity to continue to help patients and we have the right strategy.

We have the right strategy. We're focusing exclusively on medical dermatology and by partnering long term with our key customers and dermatologists.

For that and to capture this tremendous opportunity, we've been focusing on investing to making sure we develop the right platform to capture this growth, but also to develop the next wave of innovation. Now is the time to, whilst continuing this investment, to start reaping the rewards of this focus and this good investment that we've been doing until now and we are entering a new era of accelerated growth and margin expansion.

Today, also I'd like to remind you that all this growth is coming from organic growth, is coming from the assets, from the products that we already have now in our portfolio. We still keep looking for new assets either in licensing or acquisition as well.

And let me remind you what we're looking for. We're looking for assets to continue to develop our R&D pipeline so products or programs in the clinical stage, but also of course programs in clinical stage.

And also in terms of commercial, we continue to look for products in dermatology, mainly in Europe, but we're going to be looking in the US as well, if only if they had niche indications. Our strategy is working and we are delivering and we are confident in the direction of this company and in our ability to execute.

I would like now to pass back the words to Pablo for question and answer.

Thank you very much, Carlos. Nadia, back to you for the Q&A, please.

Hi there. Thank you so much.

I have just two from me, please. So firstly, just in terms of Ebglyss, what sort of penetration are you seeing in Europe if you can disclose?

And then with regards to Ilumetri, so the psoriasis market as we all know is quite saturated and the emergence of biosimilars, particularly STELARA biosimilars, might make it increasingly difficult for other players. So are you seeing any generic pressure?

What sort of drives your confidence in the increase in Ilumetri peak sales? Thank you so much.

Thank you very much for the question. So in terms of first question about Ebglyss European penetration, our strategy is to position Ebglyss as first line in naive patients and that's where the net need is in this developing and delivery market.

I am very pleased to say that we are already capturing more than double digit, we are doing the double digits in capturing this segment of naive patients first slide. And also I can say that most -- a majority of our prescriptions are in the naive space versus switch.

There's already a lot of need in the switch space but our strategy is to focus on capturing the naive and today that's working and the majority of patients that we have today are on drug are having prescribed naive patients first line. In terms of Ilumetri, we have with us Paolo Cionini Cennini, our Chief Commercial Officer, so I think that he's the best -- he can answer your question about the impact of biosimilars in the psoriasis market.

Paolo?

Thank you very much Carlos and Shan about Ilumetri and biosimilar, so we expect the overall psoriasis market to slow down a little bit with some of the products like STELARA, as you mentioned, with biosimilars happening in the market and even in 2026 with Cosentyx biosimilars, so that is what is going to happen. But on the other side we are also convinced that Ilumetri, I mean, it's playing in the IL-23 class, as Carlos has said during his presentations, so is the leading class in Europe pulling the growth in this market.

So we are convinced to be in the right class and we think also that doctors and even patients now prefer the new treatments because they are more effective than the other one. So we believe that we can continue the growth that we foresee for Ilumetri even in 2025.

And if I may add, just with the 200 milligram and the flexible dosing we are offering, I think we have a particular advantage in competing in that market.

Thank you.

Hello. Thank you for taking my question.

So, the first one regarding your guidance. What are you assuming in terms of Ebglyss?

So I understand the consensus is more or less aligned with your guidance. The midpoint is assuming around 95 million sales from Ebglyss.

Is this consistent with what you see? And the second point, in terms of milestone payments, what should we expect beyond the 45 million that you already mentioned that was paid in January?

Thank you.

Thank you, Guilherme, for questions. In terms of -- we're not providing an estimate for our Ebglyss sales in 2025, however, we are comfortable with the consensus.

In terms of the milestone payments, Mike, can you add a bit more color on this front?

Yeah. So as we look into 2025, we will pay the $45 million for Ilumetri.

If I look at the full year, we'll probably be in the 80 million to 90 million range, paying different milestones and upfronts that are related to existing agreements. That'll be slightly down from 2024.

So that's probably about the range. Now that's precluding that we make any kind of major bolt on acquisition or new end licensing, so anything that we don't have in our hands today would come on top of that.

Okay, thank you.

Hello, good morning. One follow-up from Guilherme question which in order to achieve your mid-term guidance growth, could you tell us what's the implicit levels of milestones in order to reach this 450 million Euro sales in Ebglyss and more than 300 in Ilumetri.

My second question is on the shareholder remuneration. As the company is getting into a big expansion phase on EBITDA generation with a very low level of net debt, are you thinking on increasing the shareholder remuneration or other ways to remediate the shareholders?

Thank you.

Thank you very much, Francisco, for your questions. I will leave your first question to Mike.

But answering your second question, I think it's to -- we are not prepared now to answer these questions. Something that we will -- of course, we will keep in mind.

And we will -- of course, while we prepare the AGM in May, we will be able to provide more details and more comments on that.

Yeah, so we haven't put out a complete list of milestone payments, but there are some future ones for Ilumetri and Ebglyss in particular that we could trigger if we're very successful. I would say having annual investments of all these different milestones and agreements roughly in that 80 million range for the next couple years is probably a good way to model it.

Okay, thank you very much.

Hi, thanks for taking my question. I wanted to have a little bit more detail on R&D.

It does seem that it's scaling rather quickly along with sales. You maintain this 12% of sales and I would have expected some overhead leverage on that front.

So if you could break that up on what is consuming that much R&D investment because you don't have major Phase III clinical trials, and I would have thought that the early stage pipeline was not as consuming as it is being? And also you have mentioned that the gross margin will be negatively impacted by higher royalty payments for Ilumetri.

I'm assuming something similar will happen as the Ebglyss takes a larger role on your revenue mix. Do you have any ballpark number in mind as to your mid-term gross margin?

Thank you.

Thank you very much, Alvaro, for your question. So in terms of R&D, we are keep progressing our pipeline and we keep adding assets to our clinical pipeline and we are envisaging that we're going to move -- we're going to start four proof-of-concept trials or Phase II trials within the next 15 months.

Of course, the preparation of these trials is what is consuming a substantial part of our resources and that's very exciting from our side. However, Karl, can you provide a little more color to Alvaro about his question please?

And then we can go to Mike for the gross margin question.

I think with the about 12% R&D of sales, that covers, as Carlo said, building an exciting early pipeline and starting proof-of-concept studies in the next 15 months. But it also means, and that is part of our strategy, investing in discovery, where we now have in preclinical development a bispecific antibody targeting ID [Phonetic] and as you may know, in the preclinical phase, biologics are a bit more expensive molecule, for example.

We're also working with different technology in the discovery phase as now we're seeing many scientific advances and novel approaches to treat skin diseases which allow us to generate a lot of value in the long term. And then finally also as part of this figure, we are supporting and continue support Ebglyss and Ilumetri as well as the other products that are on the market which require a lot of ongoing regulatory work.

In terms of gross margin, I would expect in 2025 probably about 30 basis points to 50 basis points of pressure versus the 64.7% we saw in 2024. As we go into the mid-term, we will continue to see a little bit more downward pressure.

I think a little bit will depend on the final pricing that we get for Ebglyss in some of the markets and how quickly we ramp up to higher royalty levels. Overall, Ebglyss should be somewhat in that range that we have today, but we may see further pressure if we hit higher royalty tiers as we go along.

So, so very clear, for 2025, 30 basis points to 50 basis points and then going forward, some kind of similar pressure, but we'll be able to quantify that better as we get to each year.

Thank you.

Thanks very much. I think we've covered most of the ground, but if I could just have a brief follow up on your proof of concept studies in the early pipeline just to get a sense of, obviously you're going to launch four POC trials immediately, but get a sense of when we might expect some data readouts on that.

Thank you.

Yes, thanks a lot. As mentioned, we are starting four proof of concept trial in the next 15 months and usually depending on the indications, those trials take about one to two years, and this gives you roughly a little bit an estimate when first readouts can be expected.

Thank you.

Yes, hello. Thank you for taking my question very quickly.

It's just on the EBITDA guidance, which is a bit broad. It's just to understand a bit better what are the levers that would allow Almirall to reach the high end of the guidance, aside from sales increase, Is it that the SG&A, you'll be able to contain it and see very small growth in SG&A because aside from that, I just can't see how you can reach that, it will be a very big margin increase.

Yeah. So if you look at the range, I mean it's 20 million, which is not a huge amount, it's about 10% or less.

But you know, to reach the high end, it's basically what you said. It's either, more robust sales, that's the easy part, or we can get done what we need to in the launches of Ebglyss and fueling the rest of the growth with a little less SG&A than the initial expectations.

So we'll be working on both of those. Ideally, of course, we'd like to hit the upper end of the ranges, but we'll see how that goes along as the year goes.

We were very pleased with the performance in 2024 and we were actually able to not only hit the high end, but slightly overachieve and we'd love to do that again in 2025.

No, sorry. Thank you.

That was perfect.

Hi, good morning. On Ebglyss, can you tell us a little bit what is the roadmap in terms of new launches in new countries?

For example, I remember in France you are negotiating the pricing with the Social Security. How is this negotiation going and what could be other relevant launches this year?

My second question would be regarding, let's call it, Almirall Legacy, so excluding derma, Q4 was particularly strong. I just want to know, I can see Almax has been growing strongly.

Also Mike was pointing out Ebastel, but I don't know if there is any one-off or any other drivers of this part. And what can we expect in 2025 in this part of the business?

And finally, maybe you can say also a word in terms of Klisyri also the growth in Europe was strong. What is driving this?

Also in the US Maybe you can tell us a little bit about the large field. How is this going and what can we expect for 2025?

And finally Seysara, also turning around Seysara China, what could we expect and when? Thank you very much.

Thank you very much Jaime. I will start with by the end and then pass the word to Paolo for your Ebglyss questions and Mike for whatever I have forgotten to answer.

But in terms of Klisyri, large field, again very strong performance in Europe -- sorry Klisyri, small field, strong performance in Europe. We are doing the clinical trials to launch the large field in Europe.

In the US what we're seeing with the large field is an increase of 40% on TRx, on total prescriptions, without cannibalizing the small field, which is a great development. We say, Seysara, we're going back to growth, which is great to see.

And in terms of Seysara China, it's too early to say. We're still waiting for the approval and the partner, et cetera and hopefully we'll be able to provide more color sometime in the next quarter or so.

Paolo, maybe you can take the Ebglyss question.

Yes, absolutely. Thank you, Jaime.

So basically there's a bunch of countries where of course we have to enter in Europe with Ebglyss. We are in negotiation phase with all of them, basically France as you've mentioned, but also Portugal and other countries in Europe.

Then you mentioned about Almax and Ebastel. So I would say that Almax we have launched four new flavors so there's an extension line on Almax that went very well.

So they didn't cannibalize after sales they had on top of that and we are very pleased about it. So as you have seen Almax has grown 24% in 2024, so very good performance and we are happy with that.

And about Ebastel, we had a very nice season -- seasonality in Europe and also we expand our business out of Europe in region international. So that's why Ebastel also performed very well in 2024.

Yeah and let me take the last question on other income type opportunities. So we basically have a line that's called other net sales.

There's a couple things in there. There's royalty income we get from products, there's out licensing income we get from non-core products that can also include territories outside of Europe and US for assets that are non-core like Tirbanibulin, Finasteride or we've also been licensing out little bits of Seysara and Klisyri rights outside that and then any kind of minor divestments.

If we look at the total in 2023 of that whole bucket was 25.7 million, in 2024 that whole bucket was 14.8 million, so a decline. And as we go into 2025 because of this minor out licensing we've done already, we would expect in the plus or minus 20 million range for the full year.

So a little decline year-on-year 2023 to 2024, a little increase in 2025 because of the January event we did. Now timing of all those things can come and go in the quarter, so nothing really particular to call out.

There was a larger amount early in 2023 and there will be of course this Q1 matter that we've already announced in the CNMV. So hopefully that gives you kind of an idea of that whole bucket.

And maybe just to add again. And thank you, Jaime, for bringing this up.

I think our strong performance in the, let's say, non-derma assets is great and contributes us a lot of resources to keep focusing on our dermatology strategy. So let's say that we are -- the combination of this portfolio is helping us a lot.

Thank you very much.

Thank you, Nadia. As there are no further questions, ladies and gentlemen, this concludes today's conference call.

Thank you for participating. You may now disconnect.